ATYR (aTyr Pharma, Inc.) Stock Financials & Earnings | Market Cap Arena

ATYR (aTyr Pharma, Inc.) Stock Financials & Earnings | Market Cap Arena

ATYRaTyr Pharma, Inc.

Mkt Cap$93M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$190,000

Net Income (TTM)-$74M

EPS (TTM)-$0.79

Free Cash Flow (TTM)-$62M

Gross Margin-11754.7%

Op. Margin-40856.3%

Net Margin-39009.5%

FCF Margin-32664.7%

P/S Ratio (TTM)488.0x

P/E Ratio (TTM)—

YoY Rev Growth-19.1%

Employees—

Earnings Reports

Next: Q1 2026 · Mar 12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	-$755K	-$13M
Q2 23	$0	-$586K	-$14M
Q3 23	$353K	-$640K	-$13M
Q4 23	$0	-$407K	-$16M
Q1 24	$235K	$235K	-$17M
Q2 24	$0	$0	-$17M
Q3 24	$0	$0	-$18M
Q4 24	$0	-$12M	-$16M
Q1 25	$0	$0	-$16M
Q2 25	$0	$0	-$20M
Q3 25	$190K	-$22M	-$27M
Q4 25	$0	-$394K	-$15M

Valuation

Quarter	P/S	P/E
Q1 23	8.9x	—
Q2 23	8.9x	—
Q3 23	8.6x	—
Q4 23	262.6x	—
Q1 24	157.7x	—
Q2 24	157.7x	—
Q3 24	394.5x	—
Q4 24	394.5x	—
Q1 25	—	—
Q2 25	—	—
Q3 25	488.0x	—
Q4 25	488.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$590K	-$2M
Q2 23	-$12M	-$14M
Q3 23	-$10M	-$10M
Q4 23	-$11M	-$11M
Q1 24	-$22M	-$22M
Q2 24	-$20M	-$20M
Q3 24	-$13M	-$13M
Q4 24	-$13M	-$13M
Q1 25	-$15M	-$15M
Q2 25	-$14M	-$14M
Q3 25	-$20M	-$21M
Q4 25	-$12M	-$12M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$1M
Q2 23	$2M
Q3 23	$557K
Q4 23	$17K
Q1 24	$17K
Q2 24	$8K
Q3 24	$15K
Q4 24	$25K
Q1 25	$0
Q2 25	$9K
Q3 25	$37K
Q4 25	$31K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+3.3%
Q2 23	—	+7.7%
Q3 23	—	-3.9%
Q4 23	-100.0%	-13.0%
Q1 24	—	+31.9%
Q2 24	—	+27.7%
Q3 24	-100.0%	+39.9%
Q4 24	—	-0.9%
Q1 25	-100.0%	-6.5%
Q2 25	—	+17.3%
Q3 25	—	+48.5%
Q4 25	—	-6.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$619K	—
Q2 23	$658K	—
Q3 23	$664K	188.1%
Q4 23	$659K	—
Q1 24	$740K	314.9%
Q2 24	$727K	—
Q3 24	$752K	—
Q4 24	$770K	—
Q1 25	$1M	—
Q2 25	$1M	—
Q3 25	$1M	687.9%
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$9M	$3M	—
Q2 23	$10M	$4M	—
Q3 23	$10M	$3M	—
Q4 23	$13M	$3M	—
Q1 24	$13M	$4M	—
Q2 24	$14M	$3M	—
Q3 24	$15M	$3M	—
Q4 24	$12M	$4M	—
Q1 25	$12M	$4M	—
Q2 25	$15M	$5M	—
Q3 25	$22M	$5M	—
Q4 25	$11M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$21M	$94M	$114M
Q2 23	$12M	$96M	$109M
Q3 23	$10M	$92M	$102M
Q4 23	$23M	$76M	$98M
Q1 24	$7M	$78M	$84M
Q2 24	$7M	$72M	$78M
Q3 24	$11M	$55M	$66M
Q4 24	$11M	$61M	$72M
Q1 25	$10M	$66M	$76M
Q2 25	$17M	$63M	$80M
Q3 25	$6M	$84M	$90M
Q4 25	$11M	$68M	$79M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	42M	+43.9%
Q2 23	55M	+31.6%
Q3 23	58M	+5.0%
Q4 23	59M	+2.4%
Q1 24	66M	+11.5%
Q2 24	72M	+9.4%
Q3 24	76M	+4.9%
Q4 24	83M	+9.1%
Q1 25	86M	+4.5%
Q2 25	90M	+4.2%
Q3 25	97M	+7.8%
Q4 25	98M	+0.9%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$0	55
FY 16	$0	58
FY 17	$0	65
FY 18	$0	42
FY 19	$10K	44
FY 20	$243K	43
FY 21	$0	53
FY 22	$148K	70
FY 23	$6K	59
FY 24	$4K	59
FY 25	$3	60K